Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Fei Ye

Fei Ye

Chinese Academy of Medical Sciences, China

Title: Characters of metabolic syndrome in high-fat-diet-induced obesity animal models — from mouse to canine

Biography

Biography: Fei Ye

Abstract

The animal models with the similar clinic pathophysiological characteristics provided a wonderful foundation for the investigation of diseases. The metabolic syndrome (MS) is characterized with obesity, insulin resistance, and glucolipide metabolic disorders. To establish a standardized experimental evaluation system, the euglycemic-hyperinsulinemic clamp test, insulin tolerance test (ITT), and level of whole body insulin sensitivity index(ISWB)was used for the insulin sensitivity; the hepatichistological analysis, triglyceride content, microcirculation, and serum alanine amino transferase levels were for the fatty liver; the glucose tolerance test (GTT) and serum lipid profiles were for the glucolipide metabolic disorders; and the hyperglycemic clamp test was for the islet function, respectively. The DIO mice or DIO canine were induced by the modified high-fat-diet in C57BL mice or Beagle canine (with fructose drink), respectively. Then, the metabonomics of serum, liver and urine was analyzed. As the results, the characters of gradually aggravated obesity, insulin resistance, impaired glucose tolerance, and liver lipid accumulation were similar in both DIO mice and DIO canines; but for the serum lipid profiles, DIO canine, DIO mice and KKay mice ( a classical MS model), each has their own characteristics. The characters of high-fat-diet-induced obesity animal models, DIO mice and DIO canine, are analogous with the progress of the MS patients. Acknowledgements: This work was supported by National Major Special Project on New Drug Innovation of China (No. 2012ZX09103-101-063; 2012ZX09301002) and Open Fund of State Key Laboratory of Bioactive Substance and Function of Natural Medicines (No. GTZK201512).